Ainda teremos antibióticos daqui a 50 anos? Perguntamos a sete especialistas globais. Veja as repostas

Published: October 17, 2023 10:52am EDT

André O. Hudson, Rochester Institute of Technology, Fidelma Fitzpatrick, RCSI University of Medicine and Health Sciences, Juliana Côrrea, Escola de Administração de Empresas de São Paulo da Fundação Getúlio Vargas (FGV/EAESP), Lori L. Burrows, McMaster University, Raúl Rivas González, Universidad de Salamanca, Roy Robins-Browne, The University of Melbourne, Yori Yuliandra, Universitas Andalas

Authors

André O. Hudson
Dean of the College of Science, Professor of Biochemistry, Rochester Institute of Technology
Fidelma Fitzpatrick
Consultant Microbiologist, Beaumont Hospital, Dublin, Ireland and Professor and Head of Department, Clinical Microbiology, RCSI University of Medicine and Health Sciences
Juliana Côrrea
Pesquisadora de pós-doutorado em saúde pública, Escola de Administração de Empresas de São Paulo da Fundação Getúlio Vargas (FGV/EAESP)
Lori L. Burrows
Professor of Biocchemistry and Biomedical Sciences, McMaster University
Raúl Rivas González
Catedrático de Microbiología. Miembro de la Sociedad Española de Microbiología., Universidad de Salamanca
Roy Robins-Browne
Honorary Professorial Fellow, medical microbiology, The University of Melbourne
Yori Yuliandra
Associate Professor of Pharmaceutical Sciences, Universitas Andalas

Disclosure statement

André O. Hudson recebe financiamento do National Institutes of Health.

Lori L. Burrows recebe verbas de pesquisa dos Institutos Canadenses de Pesquisa em Saúde, do Conselho de Pesquisa em Ciências Naturais e Engenharia do Canadá, da Glyconet e do Fundo de Pesquisa de Ontário.

Roy Robins-Browne recebeu financiamento do Conselho Nacional de Saúde e Pesquisa Médica da Austrália, do Conselho de Pesquisa da Austrália, da Fundação de Pesquisa Bill e Melinda Gates e dos Institutos Nacionais de Saúde dos EUA.

Fidelma Fitzpatrick, Juliana Côrrea, Raúl Rivas González, and Yori Yuliandra do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Partners

University of Melbourne provides funding as a founding partner of The Conversation AU.

McMaster University provides funding as a founding partner of The Conversation CA.

Universidad de Salamanca provides funding as a founding partner of The Conversation ES.

McMaster University provides funding as a member of The Conversation CA-FR.

Rochester Institute of Technology provides funding as a member of The Conversation US.

RCSI University of Medicine and Health Sciences provides funding as a member of The Conversation UK.

FGV/EAESP provides support as an endorsing partner of The Conversation BR.

View all partners

Languages

Portuguese
English

Bacteria growing on an agar plate — Shutterstock

Quase desde que os antibióticos foram descobertos, sabemos que as bactérias podem aprender a superar esses medicamentos, um fenômeno conhecido como resistência antimicrobiana.

A Organização Mundial da Saúde diz que atualmente estamos perdendo a batalha para microrganismos como bactérias, fungos e parasitas, devido ao aumento da resistência e a falta de novos antibióticos em desenvolvimento.

Queríamos saber se especialistas em alguns países do mundo acham que ainda teremos antibióticos eficazes daqui a 50 anos. Sete de cada sete especialistas disseram que sim.

“

This article was originally published in English

Want to write?

Write an article and join a growing community of more than 182,600 academics and researchers from 4,945 institutions.